LHN-1 - Logiparin
versus twice daily LMWH
No demonstrated result for efficacy
Improvement of thrombus size 2.00 [0.68; 5.85]
Mortality NaN [NaN; NaN]
Haemorraghic events NaN [NaN; NaN]
Recurrent thromboembolic events NaN [NaN; NaN]
Once daily logiparin 150 XaI U/kgp, imag (n=10)
vs.
twice daily logiparin 75 XaI U/kg (n=10)
single blind
Parallel groups
Sample size: 10/10
Primary endpoint:
FU duration: